D3 Bio raises $108M to take next-gen KRAS G12C drug into Phase 3
D3 Bio raises $108M to take next-gen KRAS G12C drug into Phase 3
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.
D3 Bio raises $108M to take next-gen KRAS G12C drug into Phase 3
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.